HEIDELBERG PHARMA AG (HPHA.DE) Stock Fundamental Analysis
Europe - FRA:HPHA - DE000A11QVV0 - Common Stock
3.12 EUR
-0.01 (-0.32%)
Overall HPHA gets a fundamental rating of 2 out of 10. We evaluated HPHA against 74 industry peers in the Biotechnology industry. HPHA has a bad profitability rating. Also its financial health evaluation is rather negative. HPHA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year HPHA has reported negative net income.
HPHA had a negative operating cash flow in the past year.
In the past 5 years HPHA always reported negative net income.
HPHA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HPHA has a Return On Assets of -48.43%. This is in the lower half of the industry: HPHA underperforms 61.84% of its industry peers.
HPHA has a Return On Equity of -248.59%. This is in the lower half of the industry: HPHA underperforms 64.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| ROIC | N/A |
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 84.66%, HPHA is doing good in the industry, outperforming 77.63% of the companies in the same industry.
In the last couple of years the Gross Margin of HPHA has grown nicely.
HPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
2. Health
2.1 Basic Checks
HPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HPHA has about the same amount of shares outstanding.
HPHA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, HPHA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -7.68, we must say that HPHA is in the distress zone and has some risk of bankruptcy.
HPHA has a Altman-Z score of -7.68. This is in the lower half of the industry: HPHA underperforms 76.32% of its industry peers.
HPHA has a Debt/Equity ratio of 3.47. This is a high value indicating a heavy dependency on external financing.
HPHA has a worse Debt to Equity ratio (3.47) than 67.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.68 |
ROIC/WACCN/A
WACC7.04%
2.3 Liquidity
HPHA has a Current Ratio of 5.85. This indicates that HPHA is financially healthy and has no problem in meeting its short term obligations.
HPHA has a better Current ratio (5.85) than 84.21% of its industry peers.
A Quick Ratio of 3.55 indicates that HPHA has no problem at all paying its short term obligations.
HPHA has a better Quick ratio (3.55) than 67.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.85 | ||
| Quick Ratio | 3.55 |
3. Growth
3.1 Past
HPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.76%.
Looking at the last year, HPHA shows a very negative growth in Revenue. The Revenue has decreased by -64.15% in the last year.
Measured over the past years, HPHA shows a decrease in Revenue. The Revenue has been decreasing by -1.29% on average per year.
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%
3.2 Future
HPHA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.35% yearly.
The Revenue is expected to grow by 6.54% on average over the next years.
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue Next Year-15.81%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HPHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HPHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HPHA's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.13%
EPS Next 3Y15.35%
5. Dividend
5.1 Amount
No dividends for HPHA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:HPHA (11/7/2025, 7:00:00 PM)
3.12
-0.01 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.34%
Inst Owner ChangeN/A
Ins Owners44.01%
Ins Owner ChangeN/A
Market Cap145.95M
Revenue(TTM)3.04M
Net Income(TTM)-26.18M
Analysts82.5
Price Target4.59 (47.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-66.91%
PT rev (3m)-66.91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)12.06%
EPS NY rev (3m)12.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 48.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.86 | ||
| P/tB | 86.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.06
BVpS0.23
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.66% | ||
| FCFM | N/A |
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
F-Score1
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40.98% | ||
| Cap/Sales | 11.76% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.85 | ||
| Quick Ratio | 3.55 | ||
| Altman-Z | -7.68 |
F-Score1
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)81.7%
Cap/Depr(5y)122.7%
Cap/Sales(3y)6.67%
Cap/Sales(5y)23.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%
Revenue Next Year-15.81%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A
EBIT growth 1Y-33.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.37%
EBIT Next 3Y3.85%
EBIT Next 5YN/A
FCF growth 1Y9.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.32%
OCF growth 3YN/A
OCF growth 5YN/A
HEIDELBERG PHARMA AG / HPHA.DE FAQ
Can you provide the ChartMill fundamental rating for HEIDELBERG PHARMA AG?
ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE.
What is the valuation status for HPHA stock?
ChartMill assigns a valuation rating of 0 / 10 to HEIDELBERG PHARMA AG (HPHA.DE). This can be considered as Overvalued.
What is the profitability of HPHA stock?
HEIDELBERG PHARMA AG (HPHA.DE) has a profitability rating of 1 / 10.
Can you provide the financial health for HPHA stock?
The financial health rating of HEIDELBERG PHARMA AG (HPHA.DE) is 3 / 10.
What is the expected EPS growth for HEIDELBERG PHARMA AG (HPHA.DE) stock?
The Earnings per Share (EPS) of HEIDELBERG PHARMA AG (HPHA.DE) is expected to decline by -44.19% in the next year.